Concepedia

Mark K. Schlegel

MK

Statistics

Publications

31

Citations

2.5K

H-Index

25

Active since

2007

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Vanderbilt University

Max Planck Institute of Colloids and Interfaces

Philipps University of Marburg

Freie Universität Berlin

Mark K. Schlegel is an author at Alnylam Pharmaceuticals (United States) specializing in molecular biology, life sciences, and rna interference.

ORCID

Publications per year

2007–2024

31

Publications

31

Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates

Donald J. Foster, Christopher R. Brown, Sarfraz Shaikh et al. · Molecular Therapy · 2018 · 308 citations · Full text

, , +17

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

Christopher R. Brown, Swati Gupta, June Qin et al. · Nucleic Acids Research · 2020 · 277 citations · Full text

, , +17

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity

Maja M. Janas, Mark K. Schlegel, Carole E. Harbison et al. · Nature Communications · 2018 · 266 citations · Full text

, , +17

Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

Kirk Brown, Jayaprakash K. Nair, Maja M. Janas et al. · Nature Biotechnology · 2022 · 245 citations

, , +16

Duplex Structure of a Minimal Nucleic Acid

Mark K. Schlegel, Lars‐Oliver Essen, Eric Meggers · Journal of the American Chemical Society · 2008 · 122 citations · Full text

, , +17

1–5 of 31